Amgen Optimistic Over Inflammation Biosimilars Ahead Of Ustekinumab
Patient Enrollment Complete For Phase III Stelara Biosimilar Study
Executive Summary
Amgen has once again touched on its impending expansion into US inflammation/immunology biosimilars, with launches for adalimumab and ustekinumab scheduled for the coming years.
You may also be interested in...
Bio-Thera’s Bevacizumab US Action Date Passes Without Approval
Bio-Thera Solutions had been hoping to become the first Chinese biosimilars developer to win an FDA approval, for its BAT1706 bevacizumab candidate. However, the announced FDA action date for the application has come and gone with no word from the company or regulator.
Coherus Moves Ahead With Pegfilgrastim On-Body Injector Rival
Coherus BioSciences is eyeing a potential late 2022/early 2023 timeline to introduce its proposed proprietary on-body injector device for its Udenyca pegfilgrastim biosimilar, after reporting positive results from a comparative clinical trial.
Bio-Thera Follows Hikma Deal With Sandoz Bevacizumab Alliance
Sandoz has plugged another gap in its off-patent oncology pipeline, from which the company has rolled-out four marketed oncology biosimilars, by bringing in Bio-Thera Solutions’ BAT1706 proposed biosimilar to Avastin, including in the US and Europe.